Zai Lab publishes AACR presentation highlighting DLL3 ADC ZL-1310 in SCLC brain metastases

• Zai Lab highlighted phase 1 monotherapy data for DLL3-targeted ADC zocilurtatug pelitecan (ZL-1310, zoci) in previously treated extensive-stage small cell lung cancer with baseline brain metastases.
• Confirmed intracranial ORR reached 53.7% (22/41) by blinded independent review using mRANO-BM; intracranial DCR was 68.3% (28/41).
• At 1.6 mg/kg, confirmed intracranial ORR was 62.5% (10/16); complete intracranial response rate was 25% (4/16).
• Safety profile was described as manageable, with grade ≥3 neutropenia 10.3% (14/136) and anemia 8.8% (12/136); grade 5 interstitial lung disease occurred in 2.4 mg/kg cohort.
• Zai Lab outlined ongoing global phase 3 DELLEVATE study in 2L+ ES-SCLC, targeting enrollment of 480 patients with primary endpoints of BICR-ORR and overall survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on April 20, 2026, and is solely responsible for the information contained therein.